Addressing an important challenge faced: How can we enhance AAV, LV, and non-viral delivery technologies to increase efficiency, tissue targeting, and reduce immunogenicity?
04 May 2026
Gene Therapy Development
- AAV: How can capsid engineering improve tissue tropism, reduce immunogenicity, and enhance transduction efficiency?
- What are the key challenges in achieving specificity in targeted non-viral gene therapy delivery?
- How can product quality assessment and impurity characterization help identify immunogenicity and toxicity risks at an early stage?
- What strategies are being developed to create immune-evasive lipid nanoparticle (LNP) formulations?
- Non-viral: How can LNP composition (ionizable lipids, helper lipids, and PEG-lipids) and formulation parameters be optimized to improve delivery performance?
Industry Expert
